Astrazeneca P L C

AZN-N

NYSE:AZN

45.07
1.55 (3.32%)
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: ...
More at Wikipedia

Analysis and Opinions about AZN-N

Signal
Opinion
Expert
BUY
BUY
January 17, 2020

They have done what Pfizer is in the process of doing. They focused in on their pipeline with drugs that are difficult to replicate. Their immunotherapy drug has been doing well, and the chart looks great. The fundamentals of the business is good. Multiples are around 13x though one of the best EPS. He is generating good premiums on his positions.

Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
January 17, 2020

They have done what Pfizer is in the process of doing. They focused in on their pipeline with drugs that are difficult to replicate. Their immunotherapy drug has been doing well, and the chart looks great. The fundamentals of the business is good. Multiples are around 13x though one of the best EPS. He is generating good premiums on his positions.

HOLD
HOLD
September 27, 2019
One of their perfect pharma holdings with well diversified and global holdings. It trades at a slight premium to the peer group, but that is warranted as it specializes in oncology. The company on has 33% of sales from the US which shelters itself somewhat from the politics of pharma. 20% of revenues come from China (where growth is 30% per year).
Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
September 27, 2019
One of their perfect pharma holdings with well diversified and global holdings. It trades at a slight premium to the peer group, but that is warranted as it specializes in oncology. The company on has 33% of sales from the US which shelters itself somewhat from the politics of pharma. 20% of revenues come from China (where growth is 30% per year).
HOLD
HOLD
July 17, 2019
AZN has a very deep phase-3 pipeline of drugs being tested and tried. The growth won't kick in until 2021-3. He loves their dividend. They've been shedding assets to focus on less price-sensitive areas. Earnings are 16x, going down to 14x in 2020. This will be a lighter quarter, because they aren't selling as many assets, but he's happy to own this.
Show full opinionHide full opinion
AZN has a very deep phase-3 pipeline of drugs being tested and tried. The growth won't kick in until 2021-3. He loves their dividend. They've been shedding assets to focus on less price-sensitive areas. Earnings are 16x, going down to 14x in 2020. This will be a lighter quarter, because they aren't selling as many assets, but he's happy to own this.
HOLD
HOLD
June 21, 2019
New oncology drugs. No problems owning it. If you're going to be in the pharma sector, buy one stock only. In the sector, half are up, and half are down. Yield is 3.3% and still growing, though not hugely.
Show full opinionHide full opinion
New oncology drugs. No problems owning it. If you're going to be in the pharma sector, buy one stock only. In the sector, half are up, and half are down. Yield is 3.3% and still growing, though not hugely.
PAST TOP PICK
PAST TOP PICK
November 14, 2018
(A Top Pick Dec 11/17, Up 30%) They'd been struggling for years, but developed a bunch of new drugs. He thinks this will rise a lot higher.
Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
November 14, 2018
(A Top Pick Dec 11/17, Up 30%) They'd been struggling for years, but developed a bunch of new drugs. He thinks this will rise a lot higher.
PAST TOP PICK
PAST TOP PICK
October 18, 2018

(A Top Pick December 11/17 - Up 18%) The whole health care sector heated up over the last year. Very safe stock to hold. Nice dividend.

Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
October 18, 2018

(A Top Pick December 11/17 - Up 18%) The whole health care sector heated up over the last year. Very safe stock to hold. Nice dividend.

PAST TOP PICK
PAST TOP PICK
March 21, 2018

(A Top Pick May 10/17, Up 16%) It's a diversified biopharma out of the UK. Surprised many by annoucning phase 2 drug trial in lung cancer--a frontrunner in this space. Their main drivers is their immunotherapy business. A great growth profile in the industry, but need to execute on a few of these trials in the next 6-12 months. Own it with BMY-N and MRK-N and not alone.

Show full opinionHide full opinion

(A Top Pick May 10/17, Up 16%) It's a diversified biopharma out of the UK. Surprised many by annoucning phase 2 drug trial in lung cancer--a frontrunner in this space. Their main drivers is their immunotherapy business. A great growth profile in the industry, but need to execute on a few of these trials in the next 6-12 months. Own it with BMY-N and MRK-N and not alone.

TOP PICK
TOP PICK
December 11, 2017

Has an impressive line of new products that should hit the market over the next 10 years, in cancer, diabetes and Alzheimer’s. They have underperformed for the last several years, and now is starting to turn the corner. Dividend yield of 4.28%. (Analysts’ Price Target is $38.)

Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
December 11, 2017

Has an impressive line of new products that should hit the market over the next 10 years, in cancer, diabetes and Alzheimer’s. They have underperformed for the last several years, and now is starting to turn the corner. Dividend yield of 4.28%. (Analysts’ Price Target is $38.)

BUY
BUY
September 14, 2017

It is rare he has puts on in his fund, but he does on this one. They have declining revenues, but a huge amount of data coming out about the next 12 to 18 months. We have seen the tip of the iceberg. He still likes it. It is not terribly expensive and has a high dividend. Own it with others for diversification. M&A would not surprise him in big pharma soon.

Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
September 14, 2017

It is rare he has puts on in his fund, but he does on this one. They have declining revenues, but a huge amount of data coming out about the next 12 to 18 months. We have seen the tip of the iceberg. He still likes it. It is not terribly expensive and has a high dividend. Own it with others for diversification. M&A would not surprise him in big pharma soon.

TOP PICK
TOP PICK
May 10, 2017

A diversified pharmaceutical, sort of shifting their business away from traditional fields. They are in decline right now on revenues. You want to be holding this along with Merck and Bristol-Myers. They have a very key study coming out, taking an immuno oncology drug and combining it with another immuno oncology drug. That is going to be a very key catalyst. Dividend yield of 4.5%. (Analysts’ price target is $34.)

Show full opinionHide full opinion

A diversified pharmaceutical, sort of shifting their business away from traditional fields. They are in decline right now on revenues. You want to be holding this along with Merck and Bristol-Myers. They have a very key study coming out, taking an immuno oncology drug and combining it with another immuno oncology drug. That is going to be a very key catalyst. Dividend yield of 4.5%. (Analysts’ price target is $34.)

BUY
BUY
October 30, 2014

Pfizer failed to acquire this company and the stock has dropped a lot. This trades at 14X earnings and has a great dividend yield and a great cash flow yield. Not expensive. Have some great things in their pipeline in the next little while, which will help the company out. Healthcare is a nice defensive area to be in if you are really worried about the stock market. (See Top Picks.)

Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
October 30, 2014

Pfizer failed to acquire this company and the stock has dropped a lot. This trades at 14X earnings and has a great dividend yield and a great cash flow yield. Not expensive. Have some great things in their pipeline in the next little while, which will help the company out. Healthcare is a nice defensive area to be in if you are really worried about the stock market. (See Top Picks.)

SELL STRENGTH
SELL STRENGTH
March 16, 2012
No, not a good entry point. Dividend for dividend sake it is a good stock. It is falling because Libitor is coming out of patent. It is an industry that is in a state of flux. It is falling off a patent cliff.
Show full opinionHide full opinion
No, not a good entry point. Dividend for dividend sake it is a good stock. It is falling because Libitor is coming out of patent. It is an industry that is in a state of flux. It is falling off a patent cliff.
DON'T BUY
DON'T BUY
November 6, 2008
You would think pharmaceuticals would be very recession resistant but it turns out it is a little more economically sensitive than would be thought. One of his concerns with the big research and development companies has been the growth of the generic companies. Also is concerned with litigation risk.
Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
November 6, 2008
You would think pharmaceuticals would be very recession resistant but it turns out it is a little more economically sensitive than would be thought. One of his concerns with the big research and development companies has been the growth of the generic companies. Also is concerned with litigation risk.
COMMENT
COMMENT
October 27, 2008
Doesn't know this as well as some of the others. Stocks he likes the most in this sector are Abbott Labs (ABT-N) and Novartis (NVS-N), which have good pipelines and good growth potential.
Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
October 27, 2008
Doesn't know this as well as some of the others. Stocks he likes the most in this sector are Abbott Labs (ABT-N) and Novartis (NVS-N), which have good pipelines and good growth potential.
DON'T BUY
DON'T BUY
September 13, 2002
Facing growing competition.
Show full opinionHide full opinion
Astrazeneca P L C (AZN-N)
September 13, 2002
Facing growing competition.
Showing 1 to 15 of 15 entries
  • «
  • 1
  • »

Astrazeneca P L C(AZN-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 4

Stockchase rating for Astrazeneca P L C is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Astrazeneca P L C(AZN-N) Frequently Asked Questions

What is Astrazeneca P L C stock symbol?

Astrazeneca P L C is a American stock, trading under the symbol AZN-N on the New York Stock Exchange (AZN). It is usually referred to as NYSE:AZN or AZN-N

Is Astrazeneca P L C a buy or a sell?

In the last year, 4 stock analysts published opinions about AZN-N. 1 analyst recommended to BUY the stock. 0 analyst recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Astrazeneca P L C.

Is Astrazeneca P L C a good investment or a top pick?

Astrazeneca P L C was recommended as a Top Pick by Paul MacDonald on 2020-01-17. Read the latest stock experts ratings for Astrazeneca P L C.

Why is Astrazeneca P L C stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Astrazeneca P L C worth watching?

4 stock analysts on Stockchase covered Astrazeneca P L C In the last year. It is a trending stock that is worth watching.

What is Astrazeneca P L C stock price?

On 2020-02-27, Astrazeneca P L C (AZN-N) stock closed at a price of $45.07.